CTOs on the Move

BI Nutraceuticals

www.botanicals.com

 
BI Nutraceuticals is a solutions-based botanical manufacturer, custom contract manufacturer, and supplier to the Dietary Supplement, Food & Beverage, Pharmaceutical, Personal Care, and Pet Care Industries. We are the leading manufacturer of whole herb powders and teas, standardized and drug ratio extracts, vitamins, minerals, amino acids, custom blends, drum-to-hopper (D-T-H) formulations, and granular ingredients. BI Nutraceuticals is committed to providing top-quality ingredients, starting even before the raw material comes through the door with our in-depth industry knowledge and distinguished vendor qualification program. The moment we receive the material it undergoes BI`s Protexx HP™ Green Steam™ sterilization, our patented high pressure, low ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.botanicals.com
  • 2384 East Pacifica Place
    Rancho Dominguez, CA USA 90220
  • Phone: 310.669.2100

Executives

Name Title Contact Details

Similar Companies

Max Courtney

Max Courtney is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Institute For Safe Medication Practices

Institute For Safe Medication Practices is a Huntingdon Valley, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

United Allergy Labs

United Allergy Labs is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Central Massachusetts Independent Physician Association

Central Massachusetts Independent Physician Association is a Worcester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cellanyx

Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.